Indeed, cinacalcet, a licensed calcimimetic drug, has been used to ameliorate symptomatic hypercalcemia in patients with FHH1 and FHH3.7, 8, 9 However, such effects of cinacalcet in FHH2 patients have not been reported, although cinacalcet has been shown in vitro, to rectify signaling abnormalities associated with FHH2‐causing Gα11 mutations.10 Here, we report the effectiveness of cinacalcet in ameliorating the signaling defects and hypercalcemia due to a previously unreported FHH2‐associated Gα11 mutation, Phe220Ser. This evidence concerns the gene GNA11 and Hypercalcemia.